US FDA Stance Against Biologics Outsourcing Draws Fire From Cell & Gene Therapy Sector
Executive Summary
Groups representing contract manufacturers and cell and gene therapy developers criticized agency’s actions forcing biologics sponsors to grapple with chemistry, manufacturing and controls challenges instead of relying on contract manufacturers’ proprietary technologies.